Revenue grew 40.82% year-over-year to ¥664.65 million, led by biopharmaceuticals and functional ingredients, but net loss widened to ¥93.85 million due to higher R&D and FX losses. Strategic deals and clinical progress support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.